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creates new forms of power with specific characteristics: the need of 
transparent subjects, the participation of patients to the power that 
aims to take control on their own body, and the growing porosity 
between the private and public sectors. First applied to the analysis 
of sexuality, the concept of biopower is nowadays highly relevant 
to analyze this new turn in medicine practices that involve the full 
cooperation and transparency of patients.
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Summary: The treatment of multiple sclerosis as an autoimmune 
disorder has benefited for several years from the progresses of bio-
therapeutics. Since the mid-1990s, interferon beta has been proposed 
as a valuable treatment for certain MS patients due to its immu-
nomodulator properties, followed shortly after by the registration 
of the polypeptide glatiramer acetate. More recently, monoclonal 
antibodies have been developed to target selective components of the 
immune response and provide a selective immunosuppression that 
could treat the disease with an acceptable safety profile. Natalizumab 
was the first of these monoclonal antibodies, and other monoclonal 
antibodies such as rituximab or alemtuzumab, originally developed 
in oncology, have since been repositioned for autoimmune disor-
ders such as MS. However, these molecules, which are very selective 
in their targets, often do not appear so favorable during develop-
ment, and their safety profile could significantly limit their use. More 
recently, the development of monoclonal antibodies has refocused 
more on targeting proteins that play critical roles in the pathophysiol-
ogy of MS, notably on the specific processes of neurotoxicity: these 
antibodies are now in early clinical development and may bring new 
avenues in the treatment of MS.
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Summary: Ever since “modern” pharmacovigilance started in the 
early 1980s, it has gone through changes of various pace introduced 
by new concepts (eg, CIOMS I-V), development of science and meth-
odologies (eg, pharmcoepidemiology), technology (eg, databases), or 
regulatory requirements (eg, risk management, new legislation). Over 
the period of time, methods of data collection and analysis became 
easier, which is helpful, taking into account the fast-growing world’s 
population. However, everyday general medical practice did not 
change much despite great progress in sciences. Large safety data are 
accessible from organized databases in regulatory bodies, industry, 
medical insurance, and other organizations, facilitating their analysis 
and aggregate evaluation, but in many situations, actions are still 
triggered by the assessment of causal associations based on medical 
judgment performed on individual cases or case reports. The future 
of pharmacovigilance should be based on well-thought-through risk 
management combined with risk minimization activities, which will 
reflect preceding appropriate benefit/risk assessment. This can be 
delivered by adequate training in clinical pharmacology, which will 
include good prescribing practices and the development of regulatory 
science either within clinical pharmacology or as a separate discipline. 
In addition, the broad understanding of important safety information 
collected and assessed from population data and in large databases 
should grow and facilitate data-driven scientific decision making.
Clinical pharmacology has an important role at present and in the 
future by providing curricula for HCPs across the world, teaching 
appropriate prescribing, risk management/minimization concepts, 
and contributing to the increase in protection of public health and 
individual patient safety by being much more prominent in the HCP 
training and clinical practice.
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Summary: Every day, European poisons centers (PC) assess poison-
ing risks of thousands of exposures to toxic agents and give advice 
for best-practice medical treatment, triggered by telephone calls from 
medical staff, patients, or caregivers. PC are continuously registering 
all exposure cases in local databases and are analyzing these data to 
detect or verify unusual poisoning events (often involving several or 
many patients) and trends of poisoning.
By this method of toxicovigilance, for example, the Swiss PC 
detected series of unexpected breathing disorders caused by regular 
intended use of 1 of 3 waterproofing spray products in 2003 and, 
more recently in 2012, the GIZ-Nord Poisons Centre in Germany dis-
covered a Ciguatera poisoning series (14 patients) generated by con-
taminated seafood (Red Snapper) purchased in local supermarkets. In 
some of these events, the toxic products identified were removed from 
shops within hours, after notifications of PCs to retail, competent 
regional, or national authorities, prevented many more poisonings.
In the past, unexpected poisoning risks that might have been caused 
by rare exposures and very rare notification to PC may have been 
missed if only single cases were notified to PC, and the cases could not 
been validated with sufficient quality. Today, networks of PC facili-
tate exchange of observations, case reports, and related toxicologic 
knowledge to rapidly confirm new or unusual poisoning risks. With 
help of conveniently new communication tools, several PC networks 
have been founded or intensified in Europe in the last decade. The 
European Association of Poisons Centres and Clinical Toxicologists 
forms the most powerful and Europe-wide expert network.
In 2011, the Public Health Project “Alert System for Health 
Threats” (ASHT, sponsored by the European Commission and the 7 
project partner organizations) had designed and tested a surveillance 
system that can collect a vast number of exposure cases reported to 
PC in real time. This system facilitates the timely concomitant analy-
sis of all cases submitted to detect unusual and hidden poisoning risk 
in a more sensitive way in the near future.
In conclusion, toxicosurveillance of population poisoning risks, 
enabled by PC’s toxicovigilance, has played an important role in 
detecting unexpected poisonings, especially poisonings caused by 
intended use of unsafe products in the past, and will play an even 
more important role in the future powered by rapidly reacting PC 
networks.
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